Kymera Therapeutics

Biotechnology company that specializes in the field of targeted protein degradation

Ticker

KYMR.NASDAQ

Trh

Rok založení

2017

Potenciál růstu

160.55%

Uzávěrka

8/27/2020

Datum IPO

8/20/2020

Cena umístění

$20

Ziskovost

60.55%

O společnosti

Total Funding

$454M

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.

Number of employees

100 - 250

Headquarters

Cambridge, Massachusetts, United States